Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RP9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RP9_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RP9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RP9_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00019613 | Oral cavity | NEOLP | positive regulation of cytokine-mediated signaling pathway | 15/2005 | 50/18723 | 1.56e-04 | 1.77e-03 | 15 |
GO:006033331 | Oral cavity | NEOLP | interferon-gamma-mediated signaling pathway | 10/2005 | 27/18723 | 2.94e-04 | 2.92e-03 | 10 |
GO:001908031 | Oral cavity | NEOLP | viral gene expression | 22/2005 | 94/18723 | 3.10e-04 | 3.05e-03 | 22 |
GO:00182122 | Oral cavity | NEOLP | peptidyl-tyrosine modification | 62/2005 | 378/18723 | 4.27e-04 | 3.91e-03 | 62 |
GO:00181082 | Oral cavity | NEOLP | peptidyl-tyrosine phosphorylation | 61/2005 | 375/18723 | 5.88e-04 | 5.08e-03 | 61 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:00506882 | Oral cavity | NEOLP | regulation of defense response to virus | 16/2005 | 69/18723 | 2.17e-03 | 1.42e-02 | 16 |
GO:00506912 | Oral cavity | NEOLP | regulation of defense response to virus by host | 11/2005 | 41/18723 | 3.12e-03 | 1.89e-02 | 11 |
GO:200102221 | Oral cavity | NEOLP | positive regulation of response to DNA damage stimulus | 21/2005 | 105/18723 | 3.45e-03 | 2.05e-02 | 21 |
GO:006033011 | Oral cavity | NEOLP | regulation of response to interferon-gamma | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
GO:006033411 | Oral cavity | NEOLP | regulation of interferon-gamma-mediated signaling pathway | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
GO:000283311 | Oral cavity | NEOLP | positive regulation of response to biotic stimulus | 29/2005 | 168/18723 | 6.52e-03 | 3.34e-02 | 29 |
GO:20007812 | Oral cavity | NEOLP | positive regulation of double-strand break repair | 10/2005 | 40/18723 | 8.10e-03 | 3.99e-02 | 10 |
GO:00507302 | Oral cavity | NEOLP | regulation of peptidyl-tyrosine phosphorylation | 41/2005 | 264/18723 | 9.51e-03 | 4.50e-02 | 41 |
GO:000641718 | Prostate | BPH | regulation of translation | 157/3107 | 468/18723 | 9.09e-20 | 5.63e-17 | 157 |
GO:007259416 | Prostate | BPH | establishment of protein localization to organelle | 142/3107 | 422/18723 | 4.01e-18 | 1.31e-15 | 142 |
GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
GO:00709728 | Prostate | BPH | protein localization to endoplasmic reticulum | 36/3107 | 74/18723 | 1.61e-10 | 9.22e-09 | 36 |
GO:009015016 | Prostate | BPH | establishment of protein localization to membrane | 77/3107 | 260/18723 | 1.06e-07 | 2.56e-06 | 77 |
GO:00725997 | Prostate | BPH | establishment of protein localization to endoplasmic reticulum | 23/3107 | 46/18723 | 1.71e-07 | 3.85e-06 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RP9 | SNV | Missense_Mutation | | c.401N>C | p.Arg134Thr | p.R134T | Q8TA86 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RP9 | SNV | Missense_Mutation | | c.169C>A | p.Pro57Thr | p.P57T | Q8TA86 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RP9 | insertion | Frame_Shift_Ins | novel | c.363_364insAAAAGGATCAATAACAAACGGG | p.Phe122LysfsTer24 | p.F122Kfs*24 | Q8TA86 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RP9 | SNV | Missense_Mutation | | c.319N>A | p.Arg107Ser | p.R107S | Q8TA86 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RP9 | SNV | Missense_Mutation | | c.283C>T | p.Pro95Ser | p.P95S | Q8TA86 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RP9 | SNV | Missense_Mutation | | c.365N>C | p.Phe122Ser | p.F122S | Q8TA86 | protein_coding | deleterious(0) | benign(0.173) | TCGA-DM-A1D6-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RP9 | SNV | Missense_Mutation | | c.663N>C | p.Glu221Asp | p.E221D | Q8TA86 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RP9 | SNV | Missense_Mutation | | c.283C>T | p.Pro95Ser | p.P95S | Q8TA86 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RP9 | SNV | Missense_Mutation | novel | c.227G>T | p.Gly76Val | p.G76V | Q8TA86 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RP9 | SNV | Missense_Mutation | rs760221836 | c.328C>T | p.Arg110Cys | p.R110C | Q8TA86 | protein_coding | deleterious(0.05) | benign(0.02) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |